Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Seeking Alpha, Healthcare Asia Magazine, Yahoo Finance and KSL News. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 36m ago.
Quick answers
Why is "Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Founday" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets TradingView · 2h ago
- Eli Lilly Stock (LLY) Rises After Company Provides Update on Obesity Pill Sales TipRanks · 2h ago
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up By Reuters Investing.com · 2h ago
- Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs Reuters · 2h ago
- Eli Lilly CEO Ricks sees more Foundayo growth with foreign markets Seeking Alpha · 2h ago
- Obesity drugs market to grow 27% across 7MM by 2036 Healthcare Asia Magazine · 2h ago
- Lilly’s Obesity Access Push via Medicare Bridge Might Change The Case For Investing In Eli Lilly (LLY) Yahoo Finance · 2h ago
- Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up KSL News · 2h ago
- Lilly's Foundayo pill wins over a third of new patients, CEO says qz.com · 2h ago
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production CNBC · 2h ago
Topics
Related trends
Trump admin won't give AI leaders a 'liability shield,' Bessent tells CNBC
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Novo Nordisk shares slide despite aggressive obesity targets as investors demand a broader long-term strategy.
Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
Chinese biopharma stocks jump as the U.S. weighs keeping the door open to drug deals.
Dollar General CEO raises major red flag about consumers
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Ernie Accorsi, legendary Giants general manager who made the shrewd move to get Eli Manning, dead at 84
Ernie Accorsi, the legendary general manager renowned for bringing Eli Manning to the Giants and leading the Cleveland Browns, has died at 84.
Russia votes in wartime election as drones strike Moscow
Russia holds a wartime election while drones strike Moscow, with the ruling pro-Putin party positioned for a comfortable victory.